IT201700025190A1 - Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa - Google Patents

Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa

Info

Publication number
IT201700025190A1
IT201700025190A1 IT102017000025190A IT201700025190A IT201700025190A1 IT 201700025190 A1 IT201700025190 A1 IT 201700025190A1 IT 102017000025190 A IT102017000025190 A IT 102017000025190A IT 201700025190 A IT201700025190 A IT 201700025190A IT 201700025190 A1 IT201700025190 A1 IT 201700025190A1
Authority
IT
Italy
Prior art keywords
membraneo
preducing
nephropathy
medications
kit
Prior art date
Application number
IT102017000025190A
Other languages
English (en)
Inventor
Gian Marco Ghiggeri
Luca Ghiggeri
Original Assignee
Pad 4 Di Emanuele Ghiggeri S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pad 4 Di Emanuele Ghiggeri S A S filed Critical Pad 4 Di Emanuele Ghiggeri S A S
Priority to IT102017000025190A priority Critical patent/IT201700025190A1/it
Priority to EP18159989.5A priority patent/EP3373008A1/en
Publication of IT201700025190A1 publication Critical patent/IT201700025190A1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT102017000025190A 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa IT201700025190A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102017000025190A IT201700025190A1 (it) 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa
EP18159989.5A EP3373008A1 (en) 2017-03-07 2018-03-05 In vitro method and kit for predicting clinical outcome in patients with membranous nephropathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000025190A IT201700025190A1 (it) 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa

Publications (1)

Publication Number Publication Date
IT201700025190A1 true IT201700025190A1 (it) 2018-09-07

Family

ID=59337790

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000025190A IT201700025190A1 (it) 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa

Country Status (2)

Country Link
EP (1) EP3373008A1 (it)
IT (1) IT201700025190A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113899908B (zh) * 2021-09-22 2024-05-28 深圳临研医学有限公司 磷酸化蛋白质在膜性肾病中的应用
CN116199795A (zh) * 2022-03-29 2023-06-02 成都地奥制药集团有限公司 融合蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009245A1 (en) * 2015-07-10 2017-01-19 Chu De Nice Prognosis and monitoring of membranous nephropathy based on the analysis of pla2r1 epitope profile and spreading

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2977758A1 (en) * 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009245A1 (en) * 2015-07-10 2017-01-19 Chu De Nice Prognosis and monitoring of membranous nephropathy based on the analysis of pla2r1 epitope profile and spreading

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRUSCHI MAURIZIO ET AL: "Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 26, no. 8, 1 August 2015 (2015-08-01), pages 1905 - 1924, XP009500345, ISSN: 1046-6673, DOI: 10.1681/ASN.2014050493 *
C. MURTAS ET AL: "Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 7, no. 9, 5 July 2012 (2012-07-05), pages 1394 - 1400, XP055409223, ISSN: 1555-9041, DOI: 10.2215/CJN.02170312 *
MAURIZIO BRUSCHI ET AL: "Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 10, 10 May 2011 (2011-05-10), pages 2008 - 2017, XP028272518, ISSN: 1874-3919, [retrieved on 20110519], DOI: 10.1016/J.JPROT.2011.05.021 *

Also Published As

Publication number Publication date
EP3373008A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2014002358A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer.
SG11201602070TA (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
DK3319651T3 (da) Vaskulariserede in vitro perfusionsindretninger, fremgangsmåder til fremstilling og anvendelser deraf
EP3464638A4 (en) USE OF BIOMARKERS TO DETERMINE SENSITIVITY TO TREATMENT OF A DISEASE
CL2015003704A1 (es) Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer
DK3343999T3 (da) Knudepunkter og fremgangsmåder til direkte adgang i dobbeltkonnektivitet
DK2964088T3 (da) Vaginalt lægemiddeladministrations- og/eller diagnosesystem
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
DK3064491T3 (da) Sulfonamidderivat og medicinsk anvendelse deraf
FI20135531A (fi) Lääketieteellinen tai hammaslääketieteellinen instrumentti ja sen valmistusmenetelmä
DK3057979T3 (da) Proteiner med diagnostiske og terapeutiske anvendelser
IT201700025190A1 (it) Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa
DK3417074T3 (da) Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro
DE112014005425A5 (de) Patiententisch zur Herstellung von NMR- und/oder CT-Aufnahmen
DK3052109T3 (da) Terapi med celler fra human placenta og hematopoietiske celler
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
EP2971163A4 (en) Tcf7l2 variant and methods of use thereof in diagnostic and drug screening assays
UA36434S (uk) Калькулятор оцінки ризику розвитку першого інсульту у хворих на гіпертонічну хворобу дисковий
FI20150314A (fi) Menetelmä rintojen tutkimiseksi ja kasvaimien todentamiseksi kudoksessa eri taajuuksilla ilmenevien fysiologisten ilmiöiden ja muutosten perusteella, käytettäväksi yhdessä tai erikseen mammografiatutkimuksen kanssa nostamaan tutkimusten sensitiivisyyttä ja spesifisyyttä
ITUB20153108A1 (it) Varianti del recettore delle cellule T e loro uso nella terapia tumorale
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PT3052476T (pt) Inibidores de nicotinimida substituídos de btk e sua preparação e uso no tratamento do cancro, inflamações e doenças autoimunes
ITUA20162220A1 (it) Tessuti bio-ibridi impiegabili nei trapianti e procedimento per la loro preparazione